QIAGEN has launched its new QIAseq xHYB long-read panels, a cutting-edge solution designed to explore the complexities of genomically diverse regions. This move strengthens Qiagen’s position as a leading provider of next-generation sequencing (NGS) solutions, offering both long and short-read technologies. These new panels are built to integrate seamlessly with native long-read platforms, including PacBio, and are designed to help researchers pinpoint a wide range of genomic variations. The panels are particularly useful in applications like HLA typing, structural variant detection, and ongoing expansion analyses, where traditional short-read sequencing faces limitations.

The Power of QIAseq xHYB Long-Read Panels

The QIAseq xHYB long-read panels, powered by QIAGEN’s hybrid capture chemistry, offer compatibility with high molecular weight DNA extraction kits, ensuring excellent uniformity and completeness of the target sequences. These panels come in flexible formats, including those for HLA typing, hereditary cancer detection, and custom panels tailored to specific research needs. Additionally, QIAGEN’s integration with its digital insights bioinformatics platform streamlines the data analysis process, making it more efficient and user-friendly.

A Key Addition to QIAGEN’s Portfolio

This launch marks a significant enhancement in QIAGEN’s portfolio, particularly for clinical and translational research in complex genomic regions. Native long-read sequencing provides deeper insights into intricate genomic areas, offering superior precision in haplotype phasing, variant resolution, and multiple detection cycles compared to synthetic long or short-read technologies. With these new panels, researchers now have the flexibility to choose between long and short-read sequencing, or even combine both approaches depending on their research goals and sample types.

Expert Perspectives

Nitin Sood, Senior Vice President and Head of Product Portfolio and Innovation at QIAGEN, commented, “This new platform is a milestone in our genomics strategy and reflects our commitment to advancing scientific discovery. It’s an important investment in our NGS portfolio, supporting key research areas like cancer biology, immune profiling, and complex diseases.”

David Miller, Vice President of Global Marketing at PacBio, expressed enthusiasm about the partnership with QIAGEN: “We are excited to expand our sequencing capabilities through this collaboration. With QIAGEN’s long-read panels, we see the power of HiFi sequencing accelerating, opening new possibilities in clinical and translational research applications.”

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com